This FERNE educational presentation examines the evolving role of brain biomarker testing in the evaluation of mTBI patients and its potential role in safely reducing unnecessary NCCT neuroimaging. The educational content reviews the GFAP and UCH-L1 biomarkers, including biomarker physiology, laboratory interpretation, diagnostic performance, and the clinical implications of false-negative biomarker results. The clinician will also gain a better understanding of how biomarker testing may reduce neuroimaging utilization and how these tests may be integrated into the Emergency Department workflow to improve patient care, operational efficiency, and clinical practice.
Why are blood-based brain biomarkers becoming increasingly important in the Emergency Department?
From watching this video the clinician will gain an understanding of the educational goals, evidence-review methodology, the practical Emergency Department application of GFAP and UCH-L1 testing, and the real-world clinical decision-making challenges involved in balancing patient safety, radiation exposure, healthcare costs, and Emergency Department throughput needs.
Pathophysiology and biologic mechanisms of mild traumatic brain injury (mTBI) biomarkers
By watching this video, the clinician will gain a practical understanding of the differences between GFAP and UCH-L1 physiology, biomarker timing windows, diagnostic strengths and limitations, and the biologic rationale supporting their use as highly sensitive adjunctive tools for helping determine the need for non-contrast head CT (NCCT) neuroimaging in selected low-risk mTBI patients.
Clinical application, diagnostic performance, and practical utility of blood-based brain biomarkers.
By watching this video segment, the clinician will also learn of the practical use of biomarkers in conjunction with clinical decision rules to safely reduce unnecessary non-contrast head CT (NCCT) neuroimaging, and how this lab testing may improve Emergency Department throughput, reduce radiation exposure, and enhance operational efficiency while maintaining patient safety in carefully selected low-risk mTBI patients.
Clinical, operational, and implementation challenges associated with blood-based brain biomarkers.
By watching this video segment, the clinician will gain a practical understanding of the clinical effectiveness, reimbursement considerations, adoption barriers, workflow integration issues, and current guideline recommendations related to GFAP and UCH-L1 testing in neurotrauma care. The learner will also better understand the operational and medicolegal considerations involved in implementing biomarker testing protocols as clinicians aim to improve the overall quality of neurotrauma patient care.
Clinical conclusions, recommendations, and future directions use of blood-based brain biomarkers
By watching this video segment, the clinician will be able to hear the conclusions and recommendations regarding the optimal use of brain biomarker testing. The clinician will gain a practical understanding of how biomarkers may be incorporated into institutional neurotrauma protocols to improve patient safety, optimize Emergency Department throughput, reduce unnecessary neuroimaging, and support more consistent evidence-based neurotrauma clinical decision-making. The clinician will also better understand the future role of point-of-care testing, AI-assisted clinical decision support, EMR integration, continuing quality improvement, and emerging biomarker technologies as Emergency Department neurotrauma patient care continues to evolve and improve.